Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library

School of Medicine

January 2013

Pilot Study Of A Somatosensory Intervention To
Improve Medical Adherence In Patients With
Uncontrolled Hypertension
Justin M. Steinberg
Yale School of Medicine, justin.steinberg@yale.edu

Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
Recommended Citation
Steinberg, Justin M., "Pilot Study Of A Somatosensory Intervention To Improve Medical Adherence In Patients With Uncontrolled
Hypertension" (2013). Yale Medicine Thesis Digital Library. 1845.
http://elischolar.library.yale.edu/ymtdl/1845

This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

Title
Pilot Study of a Somatosensory Intervention to Improve Medical Adherence in Patients
with Uncontrolled Hypertension
Author
Justin Steinberg MBA
Advisor
Christopher Ruser MD
Department
Internal Medicine
Date of Final Submission
February 15, 2013
Keywords
antihypertensive, hypertension, adherence, compliance, intervention, education,
somatosensory
Word count
17,500
Number of images
2
Number of figures
1
Number of tables
6
Acknowledgements
Christopher Ruser MD, Daniel Federman MD, Joan Lugovich RN, Nancy Kim MD PhD,
Yale StatLab Consultants’ Desk - Yale Center for Science and Social Science
Information

Abstract
Background
Essential hypertension is the most common primary diagnosis in the US, with myriad and
serious sequelae inflicting significant morbidity upon individuals and economic losses
upon society. Estimates of adherence to prescribed medication regimens range from 20%
to 60%. Because hypertension is largely asymptomatic, patients may underestimate both
the benefits of adherence and the costs of nonadherence. This novel educational
intervention seeks to encourage adherent behavior by providing patients with a conscious
manifestation of their disease severity through manipulation of pressurized balls.
Methods
Randomized controlled pilot trial of patients under treatment for hypertension with SBP
≥140mmHg or DBP ≥90mmHg at index visit, selected by convenience sample at a VA
Primary Care Clinic. Baseline clinical, demographic, medication taking habits and
motivation data obtained by surveys and chart abstraction. All subjects received a short
talk on the dangers of hypertension. Intervention Group subjects simultaneously
squeezed rubber balls in each hand filled to air pressures differing by the same amount
that their current SBP exceeded 120mmHg. Followup medication taking habits,
motivation, medication possession ratios and blood pressure measurements were
determined by telephone survey, pharmacy and clinical records over 90-, 180-, 270- and
360-day time periods. Feasibility of a larger study was determined by structured
interviews with a physician and nurse who employed the intervention in clinical practice.
Results
Thirty subjects were enrolled into Intervention and Control Groups of equal size.
Immediate motivational impact by 7-point scale significantly favored the Intervention
(6.3, p < 0.001 vs 4.3, p = 0.164). Change in self-reported adherence on an 8-point scale
at 90-days favored the Intervention but was not significant (0.5, p = 0.372 vs -0.1, p =
0.798). Change in 360-day medication possession ratio favored the Intervention and
approached significance (11.3%, p = 0.088 vs 0.7%, p = 0.934). Both Groups
demonstrated clinically relevant improvements in MAP with greater magnitude, duration
and significance for the Intervention Group through 360 days (-12.2mmHg, p = 0.008 vs
-6.0mmHg, p = 0.164). Larger improvements in adherence were significantly associated
with greater baseline motivation and immediate motivational impact from the
intervention while longer disease experiences were associated with less improvement.
Clinicians reported favorable reception from their patients and felt that the intervention
represented a simple and helpful tool that they would use in everyday practice.
Conclusions
The results of this pilot trial suggest that a novel, brief educational intervention designed
to provide a somatosensory manifestation of an otherwise asymptomatic disease process
may show promise in promoting adherent behavior and clinically useful reductions in
blood pressure in patients with poorly controlled hypertension. A larger study appears
feasible and is required to confirm and investigate the statistical significance of these
results.
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1
Introduction
Essential hypertension is the most common primary diagnosis in the United States (1).
Defined in adults as a systolic blood pressure (SBP) greater than 140mmHg or diastolic
(DBP) of greater than 90mmHg, high blood pressure has been linked to a myriad of
disorders including stroke, heart disease, renal disease, ocular disease and aortic
dissection. More than sixty-five million Americans have blood pressure high enough to
warrant treatment (2-4). Worldwide estimates of hypertension prevalence approach one
billion individuals resulting in 7.1 million deaths annually. The World Health
Organization estimates that 62% of cerebrovascular disease and 49% of ischemic heart
disease are sequelae of high blood pressure (5, 6). Other studies find that death from
ischemic heart disease, kidney disease and stroke increases progressively and linearly
with severity of hypertension (7, 8). The Framingham Heart Study found that
normotensive sixty-five year olds who live to eighty-five have a 90% chance of
becoming hypertensive in the intervening years (9). Economists estimate that the costs of
hypertension in the United States alone exceed $100 billion annually (10).

The insidious and insensible nature of hypertension makes the disease easy for the patient
to miss, minimize or deny. Approximately 30% of hypertensive adults are unaware of
their condition. More than 40% of hypertensive individuals are not under treatment and
an estimated 53% of patients do not have their SBP controlled to less than 140mmHg
(11). The efficacy of antihypertensive medicines in reducing blood pressure and the
incidence of clinical sequelae when taken appropriately is well documented (12, 13).
Failure to attain recommended targets can be due to many different phenomena including
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poor adherence to hypertensive medication and prescribed medical regimes, a problem
which is particularly prevalent in asymptomatic and chronic diseases (14, 15). Of those
who are under treatment, estimates of adherence with antihypertensive medical regimes
range from 20 to 60% (16-21). Recommendations regarding lifestyle modification are
even less likely to be followed with estimates of adherence ranging from 20% to 30%
(22). An estimated 15% of nonelective hospital admissions are due to poor medical
adherence (23) and the US Chamber of Commerce estimates the cost of poor
antihypertensive medical adherence at $13 to 15 billion per year (24). Thus, effective
approaches to improve adherence have the potential to significantly affect morbidity and
mortality in patients and decrease health care costs.

“Adherence” and “compliance” are synonyms, classically defined as the extent to which
a patient’s behaviors coincide with health care providers’ recommendations for health
and medical advice (25). Recently, medical practitioners and researchers have shifted
away from use of compliance, in favor of adherence in order to better recognize the
patient’s responsibility, agency and involvement in therapeutic decisions and encompass
their ability and willingness to abide by a prescribed therapeutic regimen (26).
Nonadherence is typically characterized as purposeful or incidental. Purposeful
nonadherence refers to willful departure from the recommendations of the physician, for
example “I just don’t think I need medication.” Incidental nonadherence involves
unintentional and nonsystematic departures from the prescribed treatment plan, for
example “I ran out of/lost my pills” (15, 27). Forgetfulness and discomfort with side
effects are consistently found to be the most prevalent explanation for incidental and
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purposeful antihypertensive nonadherence respectively (18, 28, 29). Estimates of these
components’ contributions to aggregate nonadherence vary, but one study’s findings of
42% incidental and 15% purposeful are representative of values commonly found in the
literature (15). Poor adherence manifests along a spectrum: the patient may fail to take
any medication, may discontinue prematurely or may take medication in a manner that
deviates from the prescription (30).

A significant body of work evaluates factors associated with poor adherence. Certain
demographic and clinical variables have been shown to be inconsistently associated with
compliance levels: age, gender, race, education, employment status, socio-economic
status, presence or absence of symptoms, quality of followup, complexity and duration of
regimen, side effects and certain comorbidities (15, 31-34). In addition, investigators
have examined the impact of financial, psychosocial and behavioral factors such as cost
of medication, level of insight into illness, belief in the benefit of treatment, fear of
dependence on drugs, fear or intolerance of side effects, religious beliefs, knowledge
about hypertension, support networks, quality of therapeutic alliance, access to and
satisfaction with the healthcare system, depression, internal versus external perceived loci
of control and alcohol use (35-39).

In fact, when a patient weighs their personal experience with a drug’s beneficial and
deleterious effects, costs and their understanding of the risks associated with
nonadherence, it may seem rational to forgo their medication (14, 40). Studies have
found that nonadherent patients are usually able to justify their actions through rational
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arguments that take into account their symptoms, side-effects and personal circumstances
(29). The fact that these arguments are often predicated on misunderstanding of a drug’s
purpose, side effects or symptomatic target does not lessen their weight in the decision
making process. This rationalist approach is given an analytic framework in the Health
Belief Model (HBM) which posits that people seek to avoid illness if the treatment is
perceived to be less deleterious than the illness itself as assessed along four core beliefs:
1) motivation - degree of interest in and concern about their health; 2) susceptibility perceptions of vulnerability to sequelae; 3) severity - perceptions concerning the
seriousness of the consequences of nonadherence and; 4) benefits and costs - evaluation
of the treatment’s efficacy balanced against barriers such as cost and side effects (41). In
the words of one patient, “I mean, it seems to me that like everything else it was a
question of balancing the risks. You always have risks if you have long term medication
because in a sense you become dependent on it, but on the other hand if you don’t take
them, then you risk... heart problems and strokes and all the other things which happen as
a result of high blood pressure” (42). In the HBM framework, the decision to forego the
prescribed therapy is simply the result of the patient’s personal weighting of these often
nebulous factors.

This weighting process emphasizes the importance of sufficient understanding of illness
in forming an accurate assessment of the severity of the disease and costs of
nonadherence such that they are not underestimated. Lack of knowledge of the
symptoms (or lack thereof), basic pathophysiology and treatment regarding disease
compromises the adherence decision and thus the success of outpatient therapy (43). In
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this regard, hypertension presents a particular challenge because the cues of pain and
discomfort that normally prompt people to seek and follow the advice of a medical
professional are absent. In addition, medical treatments for hypertension lack the
negative reinforcement of conscious symptom alleviation that can help drive adherence
for other maladies. As a result, treatment is encouraged through appeals to abstract
health advantages, long-term benefits and decreased risk of future disease (29). Both the
risks of nonadherence and the benefits of treatment are remote and abstract while the side
effects and cost of medication are quite real and concrete. Studies comparing betablockers prescribed for angina and hypertension found significantly lower adherence
rates for hypertension despite the fact that both diseases are associated with substantial
cardiac morbidity (44, 45). Other studies concluded that patients who perceive
hypertension as a symptomatic disease have higher rates of medical adherence (15).

Patient motivation also plays a role in adherence behavior and is interwoven with the
concepts of knowledge of costs and benefits of treatment and disease insight. One
widely-studied framework of motivation and competence, Self-Determination Theory
(SDT), posits that different kinds of motivation underlie health behaviors and thus
outcomes and exist along a continuum of autonomy (46). Autonomous, self-derived
forms of motivation (e.g. “I take my hypertension pills because I believe it is the best
thing for my health”) are associated with positive health behaviors including medical
adherence. Interventions shown to increase autonomous forms of motivation are
associated with better health outcomes (47-49). In contrast, “controlled” or externally
derived motivations (e.g. “I take my hypertension pills because others would be upset
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with me if I didn’t”) are linked to poorer adherence and well-being (50). Because
autonomy and agency are key to successful behavioral change, SDT further proposes that
health interventions require a process of proactive internalization in which people take in
and integrate the motivations and competencies initially reinforced by an external source
(e.g. physician, family members or the media) (46, 47). This process of internalization
opens up opportunities for interventions seeking to improve the health behaviors of the
poorly adherent hypertensive patient.

Given the diversity of barriers to adherence, it is unsurprising that an optimal intervention
for its improvement remains elusive. Scholars have produced more than fifty welldesigned RCTs exploring methods to increase antihypertensive adherence rates (51).
These studies can be broadly categorized into four approaches: 1) patient education, 2)
simplification of dosing regimens, 3) patient motivation, support and reminders and, 4)
complex initiatives including more than one of these approaches. These interventions
employ diverse modalities including: lecture, interactive and programmed instruction
sessions (52-55), worksite access to medical advice (56, 57), self-monitoring of blood
pressure (54, 56, 58), psychological counseling (49), reward systems (56, 58), home visits
or phone calls from care providers or researchers (53, 59, 60), and special reminder
medicine packaging (43) among many others. Design and implementation of
antihypertensive intervention studies are highly heterogeneous and their efficacy varies
widely. For example, dose simplification studies have resulted in relative improvements
of 8% (61) to 19.6% (62) as measured by pill count and electronic monitoring
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respectively. Studies of behavioral interventions cite improvements from 5% (53) to
12% (63) by self-report and pill count.

Studies of the effects of educational efforts regarding hypertension’s dangers, progression
and sequelae on adherence have produced mixed results. Some investigators have found
that the predictive value of higher levels of disease knowledge is strongest with shortterm rather than long-term treatments (64). Several studies find that frequent blood
pressure monitoring (a form of recurrent information as to disease severity) is associated
with both adherence and with return to a drug regimen for nonadherent patients (23, 65).
Researchers have found that for patients with chronic conditions, the adherence levels of
newly diagnosed patients were more likely to respond positively to educational efforts
than those with longer disease experiences (66). Often, educational efforts must
challenge well-entrenched beliefs that are at odds with the diagnosis, for example “I can’t
have hypertension because I don’t feel stressed”, or “I can’t be sick because I don’t feel
sick” (67, 68).

Meta-analyses have identified intervention types that appear to have a “significant” (but
widely varying) impact on increasing patient adherence and improving clinical outcomes
(69-73). Although not amounting to a consensus among researchers, several reviews cite
improvements following multi-approach, patient-specific interventions (69, 71, 72, 74).
Researchers have repeatedly found that successful interventions typically involve
longitudinal application of combinations of approaches and modalities. For example, in
an analysis of 16 educational interventions using indirect adherence metrics, the average
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effect size almost doubled when a behavioral component was added (71). Unfortunately,
multi-approach and longitudinal, multi-contact initiatives tend to be complex, time
consuming and expensive. As a result, reviewers cite the need for work on simpler, more
cost-effective interventions capable of being efficiently integrated into routine clinical
practice (75).

The Medical Research Council has provided guidance stressing the importance of pilot
work to refine the design of adherence interventions prior to embarking on a definitive
trial (76). As such, the aim of this project is to address the utility and feasibility of a full
scale study to add a simple, brief, patient-specific somatosensory component to the
experience of hypertension, a disease where conscious sensory feedback is otherwise
unavailable. Searches of the literature (PubMed.org on December 12, 2012) and patent
filings (patft.uspto.gov on December 15, 2012) identified no similar device for the
education of hypertensive patients and no documentation of a similar intervention.
Review of 618 manuscript titles returned for the following searches of the PubMed
Database resulted in no similar inquiries: somatosensory AND intervention;
somatosensory AND intervention AND hypertension; conscious AND intervention AND
hypertension; *symptomatic AND intervention AND hypertension.

The contemplated intervention may provide a novel, fast, safe, inexpensive and easily
performed opportunity to educate patients during the office visit with inexpensively
fabricated equipment. Providing immediacy, tangibility and urgency to the patient’s
condition - with feedback specifically calibrated to their degree of illness in the moment -
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may give impetus to greater levels of medical adherence through better understanding of
disease severity and increased levels of autonomous motivation. In keeping with the
recommendations of prior adherence improvement trials, the current inquiry implemented
a combination of previously studied metrics to capture the effects of the proposed
intervention on antihypertensive adherence (18, 30, 74).

Hypothesis
Patients with poorly controlled essential hypertension who simultaneously and repeatedly
squeeze two rubber bladders, inflated to pressures differing by the same amount that the
patient’s current systolic blood pressure exceeds its ideal level, will exhibit better
adherence to anti-hypertensive medication regimes than patients who receive no such
intervention as measured by self-report at index session and 90-day followup.

Aims
Demonstrate utility of a full-scale study through exploration of any effect on the primary
outcome of self-reported medical adherence and secondary outcomes including change in
medication possession ratios, blood pressure and motivation.

Demonstrate feasibility of a full-scale study through implementation of control and
intervention sessions, as well as interviews with clinicians who enrolled patients and
employed the intervention in the course of routine primary care practice.

Methods
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Overview
This randomized, controlled pilot study tested a five minute in-office intervention
consisting of a tactile, patient-specific representation of high blood pressure in a sample
of patients with poorly controlled essential hypertension. The intervention was
performed using a device conceived, designed and fabricated by the co-investigator.
Approval for the study was granted by the Human Subjects Subcommittee (HSS/IRB) of
the Veterans’ Affairs Connecticut Healthcare System of West Haven (VACT) and the
Human Investigation Committee (HIC) of the Yale School of Medicine. The study was
performed under the supervision of an Associate Professor of Internal Medicine who is
an attending physician in the Clinic and served as Principal Investigator.

Inclusion and exclusion criteria
Eligible patients included any patient over eighteen years old treated at the VACT
Primary Care Clinic between June 15, 2010 and August 15, 2010 with diagnosis of
essential hypertension by ICD-9 in the patient’s Problem List and SBP at check-in of
≥140mmHg or DBP of ≥90mmHg and an active prescription for medications from the
following classes: diuretics, beta blockers, ACE inhibitors, angiotensin II receptor
blockers, calcium channel blockers, alpha blockers, combined alpha and beta blockers,
central agonists, peripheral adrenergic inhibitors, vasodilators and sympathetic inhibitors.
Included patients must have been able to provide a current home address and phone
number.
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Ineligible patients included those under eighteen years old, no diagnosis of essential
hypertension prior to index session, no home address or phone, pregnant, incompetent to
consent, non-English speaking, unable to perform the intervention, unable or not
expecting to attend followup appointment, and those with any comorbidities that would
raise the risk or pain associated with the mild physical exertion necessary to perform the
intervention: history of myocardial infarction, history of stroke, history of congestive
heart failure, on supplementary oxygen, upper extremity arthritis, upper extremity
vascular compromise, or recent upper extremity surgery. Patients were also excluded if
the care provider felt that the patient should not participate for any reason. Exclusion of
patients with history of advanced vascular compromise or atherosclerotic disease was
intended to minimize the possibility of adverse events related to effort expended during
the intervention.

Funding
The co-investigator received $5,244 from a National Institutes of Health NHLBI
Research Fellowship.

Conflicts of interest
The co-investigator and Yale University are co-holders of a provisional patent on the
design of the device.

Prior presentation
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Preliminary results were reported at the AMA Medical Student Research Symposium in
2010.

Recruitment and setting
Investigators recruited a convenience sample of patients presenting for regularly
scheduled or acute primary care visits at the VACT Primary Care Clinic from June 15
through August 15, 2010.

Every morning, a clinical room and a roster of the day’s patients were made available to
the co-investigator. The co-investigator pre-screened patients with diagnoses of essential
hypertension and active prescriptions for antihypertensive medication via chart review
using the VA Computerized Patient Record System (CPRS). Prior to being seen by their
physician, all patients underwent evaluation by a staff healthcare provider including
assessment of vital signs. If the SBP recorded at check-in was ≥140mmHg or DBP
≥90mmHg and no exclusions were present, the co-investigator placed a note in the
patient’s file indicating that they appeared to qualify for the study and asking the treating
physician to discuss study participation if time permitted. If the patient indicated interest,
the caretaker introduced the patient to the co-investigator at the conclusion of the primary
care visit. The co-investigator then confirmed that the inclusion and exclusion criteria
were met. Subjects then participated in the informed consent process as guided by the
co-investigator.

Randomization
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Upon completion of the consent process and after any questions were addressed, the
subjects were randomized and assigned to one of two Groups - Intervention or Control according to a pregenerated list of 0’s and 1’s using the Excel =RAND() function. For
practical reasons, the co-investigator could not be blinded to Group assignment as they
delivered the intervention and also collected, entered and analyzed the data. Moreover,
the subject’s active participation precluded their blinding to whether or not they received
the intervention.

Groups
All patients from both Groups underwent the same session at index visit including filling
out surveys, listening to an educational script on the dangers of uncontrolled hypertension
and followup as outlined below. The Intervention Group received the somatosensory
pressure demonstration during the index visit whereas the Control Group did not.

Demographic questionnaire and baseline clinical data
Subjects from both the Control and Intervention Groups underwent a short investigatoradministered demographic survey including questions on age, gender, race and marital
status. Subjects were also asked to provide contact information (address and telephone
number) for followup. Additional patient profile data were later abstracted from the chart
including date of hypertension diagnosis, comorbidities, number of medications and
number of antihypertensive medications. The number of index hypertension medications
was calculated by taking the average number of active scripts for the 30 days preceding
the index visit.
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Motivation and adherence habits questionnaires
Subjects were then prompted to complete a series of Likert-scale and yes/no questions to
the best of their ability. Research staff left the room for 5 minutes; if subjects required
any clarification, it was given by the co-investigator before proceeding to the next stage
of the session. Self-administration of the questionnaires was intended to reduce observer
bias.

Subjects first completed the Treatment Self-Regulation Questionnaire (TSRQ) (Image 1,
left), a twelve-item questionnaire designed to assess baseline motivation levels. The
TSRQ is a theoretically derived scale that assesses the degree and origin of motivation
possessed by patients contemplating medical treatment or healthy behavior. The
questionnaire was developed by the NIH Behavioral Change Consortium (77, 78) and has
been widely employed to gauge “controlled” and “autonomous” or “internal” motivation.
It has been validated across several settings and health behaviors (50, 79-83). The
wording of the generic questionnaire was modified to provide relevance to
antihypertensive medical adherence. Subjects used a 7-point Likert scale to rate their
agreement with each item describing the reasons they would take their hypertension
medications as prescribed to them (1 = not true at all, 7 = very true) for a total possible
score of 84 evenly divided between autonomous and controlled metrics.

Prior studies have found that autonomous motivation in initiating behaviors is associated
with greater sense of perceived competence in carrying out those behaviors and with
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positive health behaviors including adherence to medication regimens (48, 83, 84). One
study of HIV antiretroviral adherence found autonomous components of the TSRQ
associated with better dose timing but not with dose adherence (84). Another inquiry
concluded that positive changes in autonomous motivation were found to predict
improvement in glycemic control for patients with chronic diabetes (48).

Questions 1-6 of the TSRQ relate to autonomous forms of motivation in which behavior
finds its antecedents in volition and choice. Questions 1-3 focus on “identification”
wherein behavior is positively endorsed and valued by the individual. Questions 4-6
relate to “integration” in which a behavior is perceived as being part of the larger self and
connected to broader values and goals.

Questions 7-12 consider controlled types of motivation. Items 7 and 8 explore
“introjected” regulation in which behaviors are performed to avoid feelings of guilt.
Questions 9-12 consider “external” motivation which drives behaviors performed in order
to obtain a reward or to avoid negative consequences (50, 64).

Subjects were then prompted to complete the Morisky Medication Adherence Scale
(MMAS) (Image 1, right), an eight-item questionnaire designed to assess baseline
adherence levels (85). The questionnaire was recently developed as an improvement
upon a widely used four-item assessment (86) and has been shown to have a strong,
graded and statistically significantly association with anti-hypertensive medical
adherence as measured by electronic Medication Event Monitoring System (MEMS) and
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pharmacy refill records (87). These studies also confirm the predictive validity of the
MMAS for adequate blood pressure control (85, 87).

Each of the eight items measures a specific medication taking behavior and not a
determinant of adherence such as motivation. Each question is scored 1 for “no” and 0
for “yes” with the exception of question 5 which is reverse coded and question 8 which
uses a 5-point Likert scale and is coded fractionally. Aggregate scores for the MMAS are
typically segregated into three levels of adherence: a perfect score of 8 corresponds to
“high” adherence, 6 to < 8 indicates “medium” adherence, and a score of < 6 is
associated with “low” adherence. The primary validation study for the MMAS found that
67.2% of low adherers had uncontrolled blood pressure compared to 55.2% and 43.3% of
medium and high adherers respectively. The same study found that scores of 6 or greater
had 93% sensitivity and 53% specificity for adequately controlled blood pressure (85).

The use of questionnaires was thought to provide a compromise between simpler but less
reliable assessments such as interviews and more complex or invasive methods that may
be more accurate (22, 88, 89). Although easy and cheap, interviews are subject to
distortion due to socially desirable answers, approval-seeking, variable interviewer
experience, phrasing and interpersonal dynamics. Self-administered questionnaires have
the advantages of prior validation, ease of administration and the possibility of providing
explanations for adherence behavior (as opposed to pharmacy data). Disadvantages of
this approach include discontinuity of the data and the fact that the accuracy of the results
depend on the instrument chosen (30). MMAS questions are phrased in the negative to
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counter the tendency of patients to respond to questions in healthcare settings in the
affirmative (89).

Although considered the gold standard for indirect adherence measurement, electronic
monitoring of pill usage via MEMS (30) was not practical due to cost. Direct measures
of adherence such as blood tests for drug or metabolite levels, biological markers or
direct observation of the subject receiving medications were not feasible with the
resources available to the investigators and are subject to their own disadvantages (90).
Image 1. Motivation (TSRQ) questionnaire (left), adherence (MMAS) questionnaire (right)
For each item, please circle the number from 1 to 7 that best expresses your beliefs:

1. I take my high blood pressure medications because it is very important for being
as healthy as possible.
Not true
Very
1
2
3
4
5
6
7
at all
true
2. I take my high blood pressure medications because it is the best thing for my
health.
Not true
Very
1
2
3
4
5
6
7
at all
true
3. I take my high blood pressure medications because I want to take responsibility
for my own health.
Not true
Very
1
2
3
4
5
6
7
at all
true
4. I take my high blood pressure medications because it is a choice I really want to
make.
Not true
Very
1
2
3
4
5
6
7
at all
true
5. I take my high blood pressure medications because it is very important for many
aspects of my life.
Not true
Very
1
2
3
4
5
6
7
at all
true
6. I take my high blood pressure medications because it is consistent with my life
goals.
Not true
Very
1
2
3
4
5
6
7
at all
true
7. I take my high blood pressure medications because I would feel guilty or ashamed
of myself if I didn’t.
Not true
Very
1
2
3
4
5
6
7
at all
true
8. I take my high blood pressure medications because I would feel bad about myself
if I didn’t.
Not true
Very
1
2
3
4
5
6
7
at all
true
9. I take my high blood pressure medications because I feel pressure from others
(family, friends, care providers, etc) to take them.
Not true
Very
1
2
3
4
5
6
7
at all
true
10. I take my high blood pressure medications because others (family, friends, care
providers, etc) would be upset with me if I didn’t.
Not true
Very
1
2
3
4
5
6
7
at all
true
11. I take my high blood pressure medications because I want others (family,
friends, care providers, etc) to see I can do it.
Not true
Very
1
2
3
4
5
6
7
at all
true
12. I take my high blood pressure medications because I want others (family,
friends, care providers, etc) to approve of me.
Not true
Very
1
2
3
4
5
6
7
at all
true

For each item, please circle the answer that best expresses your beliefs:
1. Do you sometimes forget to take your high blood pressure pills?
Yes

No

2. Over the past two weeks, were there any days when you did not take your high
blood pressure medicine?
Yes

No

3. Have you ever cut back or stopped taking your high blood pressure medicine
without telling your doctor because you felt worse when you took it?
Yes

No

4. When you travel or leave home, do you sometimes forget to bring along your high
blood pressure medicine?
Yes

No

5. Did you take your high blood pressure medicine yesterday?
Yes

No

6. When you feel like your blood pressure is under control, do you sometimes stop
taking your medicine?
Yes

No

7. Do you ever feel hassled about sticking to your blood pressure treatment plan?
Yes

No

8. How often do you have difficulty remembering to take all your blood pressure
medication?
Almost
Quite
Never
Sometimes
Always
never
often

Informational script - the importance of BP management
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Following completion of the questionnaires, the co-investigator delivered a short, scripted
talk on the importance of hypertension management derived from the American Heart
Association publication What is High Blood Pressure?
“High blood pressure means the pressure in your arteries is elevated.
Blood pressure is the force of blood pushing against blood vessel walls.
No one knows exactly what causes most cases of high blood pressure. It
usually can’t be cured, but it can be controlled. High blood pressure
usually has no symptoms. So many people have it and don’t know it.
Not treating high blood pressure is dangerous. High blood pressure
increases the risk of heart attack and stroke and can damage your kidneys.
You can live a healthier life if you treat and control it. Things that you
can do to help control your blood pressure include taking your medicine
the way your doctor tells you.
Some medicines, help relax and open up your blood vessels so blood can
flow through better. Other medicines keep your body from holding too
much water and salt or help your heart beat more slowly and with less
force.” (91)

Intervention
Subjects randomized to the Intervention Group then participated in a session intended to
provide tactile feedback demonstrating the difference between the subject’s blood
pressure as measured at check-in and the target pressure recommended by their doctor.
Tactile feedback was provided by two rubber balls constructed out of commonly
available sphygmomanometers in which the cuff’s nylon covering was removed and the
rubber bladder stuffed inside the distal portion of a cotton sock and secured with zip-ties,
resulting in an inflatable ball of roughly spherical shape (Image 2). Upon inflation to the
desired pressure, the rubber hoses leading to the bulb and gauge were clamped using
hemostats to prevent air leakage.
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One rubber ball was inflated to 20mmHg (the Reference Ball). A second ball was
inflated to 20mmHg plus the difference between the patient’s current SBP and their ideal
SBP (the Hypertensive Ball). For example, if the patient’s SBP measured at check-in
was 160mmHg and their ideal SBP is 120mmHg, the Hypertensive Ball was inflated to
20 + (160 - 120) = 60mmHg. The subject was then informed that the difference between
the two balls was equal to the difference between their actual blood pressure and “where
your doctor thinks it should be”.

The subject was then asked to take one ball in each hand and squeeze them both
repeatedly and simultaneously until one arm felt fatigued or for one minute, whichever
occurred first. The co-investigator monitored the time using a wristwatch. In informal
testing, noticeable unilateral fatigue was reached at approximately 30 squeezes over 20
seconds with a Hypertensive Ball pressure of 60mmHg and a Reference Ball pressure of
20mmHg.

Intervention script - extra workload on the heart
The co-investigator then discussed with the Intervention subject the analogy of this
fatigue with the added work that is being demanded of their heart due to the same extra
pressure against which it is constantly and unceasingly working. The script emphasized
that the difference in work/fatigue that their arms are experiencing is the same as the
difference between the resistance that healthy blood pressure would present to their heart
and its current burden. Furthermore, while their arm can send conscious signals of
fatigue, stop working and recuperate, the heart’s signals of pain and fatigue do not rise to
the level of consciousness and it does not get to rest.
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“The difference between the bladder pressures is equal to the difference
between your blood pressure right now and where your doctor thinks it
should be. In about half a minute, you were able to feel the difference in
work that your arm had to exert working against the higher pressure. You
heart has to do the same thing, day in and day out without a break. Your
arm can send signals to your brain saying that it’s tired and so it gets to
rest. But while your heart is working harder, you don’t experience the
fatigue at a conscious level. The medications that your doctor has
prescribed for you will help lower the amount of work that your heart has
to do.”
The use of scripts for conveying information to subjects was intended to ensure
consistency of delivery between sessions.

Image 2. The intervention device consisted of two modified sphygmomanometers with the inflatable bladders repurposed to
expand within a spherical cotton sleeve (photo taken by the author using a digital camera)

Assessment of immediate motivational impact
All Intervention and Control subjects were then asked the following question: “On a
scale of 1 to 7 with 1 being much less motivated and 7 being much more motivated, how
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has this session changed your motivation to take your blood pressure medication?” A
score of 4 represented “no change in motivation”. This question was conceived by the
investigators as a way of evaluating patients’ “gut” reaction to the session outside of any
more durable changes in motivation or behavior. It was also considered a way of
collecting viable motivation data in case of outsized losses to followup.

Demographic, TSRQ, MMAS data and immediate motivational scores were recorded by
the co-investigator on a deidentified Excel spreadsheet stored on a secure VACT server.
All original paper documents including consents and questionnaires were stored in a
locked cabinet in the principal investigator’s locked office.

Followup and chart abstraction
Subjects were contacted 90 days following the index session for readministration of the
TSRQ and MMAS via telephone. If the subject was not available, a message was left
requesting a callback. If the subject did not call back within 72 hours, another attempt
was made. A maximum of three such attempts were made per subject after which the
subject was deemed lost to followup. During these calls both the TSRQ and MMAS
questionnaires were administered by the co-investigator for comparison to those of the
index session.

Followup blood pressure data from all patients were abstracted from CPRS from
regularly scheduled Clinic appointments within +/- 15 days of 90, 180, 270 and 360 days
following the index session. Patients with recent hypertension diagnoses typically
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receive check ups every four to six weeks to determine drug tolerance, efficacy,
adherence and to address any of the patient’s questions or concerns. Adjustments to
treatment regimen are frequently made at this time. For patients with long-established
hypertension, appointments every three to six months are typical of the course of care.
“BP check” appointments are also common and while not a full visit, constituted
opportunities to gather outcome data. If no such visit was recorded within the
appropriate date range, the subject was considered lost to followup for that period.
Patients could be lost to followup for one period but have a qualifying visit for a later
period. For example, several subjects had no qualifying visit 270 days after the index
session, but did have a “yearly” visit at 360 days.

In keeping with prior studies, subjects’ pharmacy data were extracted to determine the
Medication Possession Ratio (MPR) for the 360-day periods preceding and following the
index session (87, 92-94). The VA maintains electronic records of prescriptions written
by clinicians (“scripts”) and patient pharmacy activity (“fills”). The co-investigator
abstracted script data from CPRS including data on all hypertension medications for each
subject with active date ranges in 2009, 2010 or 2011. The abstracted fields included
medication name, pill count, dosage instructions, start date and end date of the script. Fill
data consisted of blocks of dates defined by the date on which the patient filled a
prescription for a hypertension medication (either in person or via mail) plus the number
of days supplied as implied by the pill count and dosage instructions (e.g.: “½ tablet three
times per day”). The resulting sets of date ranges allowed for comparison between the
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number of antihypertensive scripts written and filled for any date between 1/1/2009 and
12/31/2011 for each subject.

If a subject had a script that covered a given day and had not filled that script, the
resulting score would be 0 for the medication for that day. Conversely, if the fill data
indicated that a subject was in possession of the medication on that day, the score would
be 1. A given day’s Medication Possession Ratio (MPR) was the sum of such values
divided by the total number of scripts covering that day. For example, if a patient had 4
antihypertensive scripts whose valid dates covered a given day and on that day the
patient’s fill data indicated possession of only 3 medications, the MPR for that day would
be 0.75. Outcome MPR measures were then computed using the average of such ratios
over the 360 days preceding and following the index visit.

Days which were not covered by a script were not included in the denominator of the
MPR. It was believed that this approach provides a more accurate assessment of
adherence compared to methods used elsewhere which appear to assume that 100% of
days were covered by a prescription and so calculate MPR using a fixed 360 or 365 days
in the denominator (95). In the case where a physician neglects to write a script, such an
assumption would result in an artificially depressed value for adherence. A minority of
patients filled their prescriptions outside the VA system, had no CPRS data for these fills
and were excluded from this part of the analysis.
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A cutoff of 80% by pharmacy data is widely used in the literature to define adequate
medication adherence for a number of diseases. In the study of antihypertensive regimes,
this threshold has been associated with a level of drug consumption below which
adequate control of blood pressure was less likely to be achieved across a number of drug
classes (17, 96-100). While this threshold has been criticized by authors as arbitrary and
overbroad in its application - substantial numbers of non-compliant patients by this
metric have controlled blood pressures (21) - its use is nevertheless widespread in
adherence literature and will be employed for this analysis.

All followup, script and fill data were recorded by the co-investigator on a deidentified
Excel spreadsheet stored on a secure VACT server.

Feasibility
A second protocol was written and approved for July 15, 2011 to August 15, 2011 during
which a VACT Clinic doctor and a nurse specializing in care of hypertensive patients
used the intervention to educate their patients on their disease process. The intervention
employed during these sessions differed from the RCT in several important ways: the
clinicians were free to use the script as they saw fit, explaining the intervention in their
own words if they found that less disruptive to the rhythm of the clinic visit; the device
employed during these sessions was substantially modified from that originally used in
order to facilitate a faster intervention; and, because no followup comparisons were
contemplated for these subjects, no baseline questionnaires were employed.
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Structured interviews of both practitioners were performed via email in order to assess
the practicality and utility of the device in everyday clinical use. The results of these
interviews were used to inform questions regarding the feasibility of a larger study and
overall clinical utility.
The questions used for the interviews were as follows:
How easy was it to find patients for the intervention?
Was it easy to get people to agree to participate?
Did patients seem interested in the intervention?
How easy was it to operate the device?
How long did a typical intervention take you?
How much of this time was paperwork vs the actual demonstration?
Do you think this intervention could be incorporated into your clinical practice?
Would you use this intervention if the device was available to you?
Do you think incorporating this intervention would be useful to your patients?
Do you think this intervention will encourage your patients to change their adherence
behavior?
Do you think this intervention is particularly well or poorly suited for particular patients?

Outcome measures
The primary outcome of interest is subject adherence to regime of prescribed medication
as determined by MMAS at index session and at 90-day followup. Patient self-reporting
is direct, simple and inexpensive (101). Although self-report alone may lead to
overestimates of adherence, many studies have compared self-report and other
assessment methods with favorable results and correlate improved levels of self-reported
adherence with better blood pressure control (102-107). While a metaanalysis of 86
studies comparing self-report with nonself-report measures found that only 17% of selfreport measures were highly concordant with electronic measures, questionnaires
presented the highest concordance (58%) of the self-report methodologies (108).
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Adherence to an antihypertension regime includes an array of actions beyond timely
consumption of one or more medicines. A number of different behaviors are also
prescribed: losing and maintaining weight, reducing sodium intake, quitting smoking,
reducing consumption of alcohol, initiating exercise and returning regularly for checkups
to name a few. The sheer diversity of these behaviors suggests that a patient’s adherence
may vary across categories of prescribed activity. The variable and interacting
contribution of each behavior to the ultimate goal of lowered blood pressure means that
simply counting the number of pills the patient takes home from the pharmacy or miles
logged on a treadmill is unlikely to result in an accurate assessment of adherence.
Change in blood pressure would seem to be a sufficient measure of adherence, however
there is often not a straightforward link between this outcome and medical adherence
(43). The patient may be obtaining lower blood pressure because of weight loss, exercise
or even reassurance from the physician or family. Conversely, a failure to achieve a
lower blood pressure may be due to poor physiological response to a rigorously followed
drug plan. Thus, a focus on blood pressure alone may lead to an incorrect evaluation of
regimen adherence.

Because no single metric has proven optimal in accurately gauging medical adherence
(30, 109) four additional metrics were employed to validate and assess the clinical
significance of the results of any changes in the MMAS: a 7-point Likert scale gauging
the subject’s sense of any change in adherence motivation administered immediately
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following the session, electronic prescription fill data, changes in motivation as measured
by the TSRQ and changes in blood pressure.

Finally, the question of feasibility of a larger study was addressed through structured
interviews with a primary care doctor and nurse who used the device and intervention in
their own clinical practices.

Pilot study sample size
The anticipated sample size for a full study of this intervention is 120 patients. This
number is rounded upwards to account for anticipated losses to followup from 102 which
was the sample size indicated by a standard statistical method for such approximation of
difference of proportions (Figure 1). The equation was bounded by the following
targets/assumptions regarding the primary outcome (change in MMAS): a target p-value
of 0.05, statistical power of 0.80, standard deviation of 1.6 and a clinically important
difference between Groups (size effect) of 0.8 on the 8-point scale in keeping with prior
studies using the same questionnaire (110). This sample size also agrees with a widely
employed rule-of-thumb which suggests a minimum of 60 participants per Group for
single intervention group adherence RCTs (111).

In accord with the recommendations of the Medical Research Council, it was decided that
a pilot study of 30 subjects was required before embarking on the larger inquiry given the
novelty of this intervention. In addition, enrolling 120 subjects would require staffing
and funding beyond what was feasible with available resources. While there is no
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standard in the literature to guide sample size determination for interventional pilot
studies (112), 30 subjects corresponds to a MMAS size effect of 1.5 points (all other
assumptions unchanged) which was believed to provide a reasonable balance between a
realistic target and a workable recruitment goal.
Figure 1. Sample size required to detect various MMAS change size effects (σ = 1.6, p = 0.05, power = 0.80)
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Statistical analyses
Statistical analyses of continuous data included descriptive statistics, Pearson’s and
pairwise correlations, OLS regression and t-test comparisons. Categorical adherence
measures were analyzed for correspondence and intergroup differences using chi-squared
analysis and Fisher’s exact tests. All computations were performed using Excel for Mac
v. 14.2.0 (Microsoft Corporation, Redmond, WA) and Stata v. 10.1 (StataCorp, College
Station, TX). Results were considered statistically significant at the 5% level (p < 0.050).

Results
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Demographics
Thirty subjects were enrolled from June 15 to August 15, 2010 resulting in Intervention
and Control Groups of 15 patients each. All were male veterans with no statistically
significant differences in demographics or baseline clinical data between Groups (Table
1).

The mean age of subjects was 69.7 years (95% CI: 65.3, 74.1) with a range of 44 to 88
years. The majority, 21 (15.8, 26.2) were Caucasian with the remainder of subjects
identifying as African American. There were 14 (8.3, 19.7) married subjects evenly
distributed between Groups. The remaining subjects were either divorced (6 subjects),
separated (1 subject), widowed (4 subjects) or single (5 subjects). The average duration
of hypertension diagnosis at index session was 8.1 years (6.2, 9.9). Subjects in the
sample had an average of 11.4 (9.1, 13.6) comorbidities (including hypertension) at
index. The average subject took 8.0 (6.2, 9.7) different prescribed medications at the
time of index session, including 2.9 (2.1, 3.7) hypertension medications. The average
number of antihypertensive scripts increased by 0.6 (p = 0.025) during the index visit
without significant differences between Groups (p = 0.866).

Baseline blood pressures
Index session SBP, DBP and MAP had no statistically significant differences between
Control and Intervention Groups (Table 1). The mean SBP for the sample was
155.7mmHg (150.2, 161.2), mean DBP 81.9mmHg (76.3, 87.6) and mean MAP of
106.5mmHg (101.8, 111.2). Only 9 of 30 subjects were hypertensive by both systolic
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(≥140mmHg) and diastolic (≥90mmHg) measures, the majority being hypertensive by
systolic blood pressure only.

Index SBP was negatively correlated with index medical adherence as measured by both
MPR and MMAS. Those categorized with low, medium and high MMAS had mean SBP
of 164.5mmHg (152.8, 176.2), 150.0mmHg (143.7, 156.3) and 153.3mmHg (141.4,
164.6) respectively. Between Group differences in index SBP were noted by ANOVA
for these categories with borderline significance (p = 0.058). However, no significant
difference in baseline blood pressure was found between those categorized as adherent by
MPR compared to nonadherent, with mean SBP of 157.8mmHg (139.3, 176.3) and
156.3mmHg (149.3, 163.2) respectively. Blood pressure had no other significant
correlations with demographic or other index visit variables (Table 5).

Baseline motivation
Baseline adherence motivation was statistically indistinguishable between Intervention
and Control Groups. Mean index session TSRQ was 52.9 (48.7, 57.1) out of a possible
84 points with roughly two-thirds of the contribution from autonomous motivation (Table
1). Mean baseline TSRQ was slightly lower in the Intervention Group for both controlled
and autonomous subtypes. Index adherence motivation was negatively correlated with
duration of disease, number of comorbidities and number of medications (Table 5).

Baseline adherence
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There were no significant differences between Intervention and Control Groups in
baseline adherence both in groupwide mean measurements and when the data were
analyzed categorically (Table 1). Self-reported adherence for the sample as a whole, as
measured by mean MMAS was 6.0 (5.2, 6.8) out of a possible 8, which is categorized as
a “medium” level of adherence according to questionnaire validation studies (85).
However, the baseline mean 360-day MPR was 54.6% (42.6, 66.8), well below the
commonly employed 80% adequacy threshold.

As reported elsewhere and consistent with a relatively low specificity of 53% (85), mean
self-reported scores appeared to overstate adherence levels when compared to pharmacy
fill data (16, 17, 113). The majority, 66.7% (52.6%, 87.4%) of subjects self-reported
medium or high levels of adherence by MMAS. In contrast to MMAS, less than one
quarter of subjects, 23.1% (5.7%, 40.4%) were classified as adherent by medication
possession. Index MPR was lower in the Intervention Group but the difference was not
statistically significant.

The two metrics for index medical adherence were positively correlated with a significant
slope coefficient indicating an 8.6% (4.3, 12.9) increase in fill rates for every 1 point
increase in self-reported adherence (R2 = 0.418) (Figure 2, left). Chi-squared measure of
association between the categories of adherent/nonadherent for MPR and
low/medium/high for MMAS was suggestive of good concordance but of borderline
significance (χ2 = 4.178, p = 0.124). Fisher’s Exact test resulted in similar significance (p
= 0.157). Of the 6 subjects who were adherent by MPR, none were “low” adherers by
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MMAS, 3 were classified as “medium” and 3 were “high”; of the 20 subjects classified as
nonadherent by MPR, 9 were “low” adherers by MMAS, 6 were “medium” and 5 were
“high” (Figure 2, left).

The inverse relationship between MMAS and baseline blood pressure noted above is
consistent with the results of prior studies (85). For the study sample, each 1 point
increase in MMAS was associated with a 3.1mmHg (-0.7, -5.5) decrease in index SBP
(R2 = 0.202) (Figure 2, right). The average SBP for medium and high adherers by
MMAS was 151.8mmHg and 165.7mmHg for low adherers. As with MMAS, higher
levels of MPR appeared to predict lower index blood pressure (-16.7mmHg SBP per 10%
increase in MPR). However, the sample size was insufficient to establish the significance
of this relationship.

In addition to lower index blood pressure values, better results for both adherence metrics
were associated with lower scores for controlled motivation, higher scores for
autonomous motivation, longer duration of disease and Caucasian race. The strength and
significance of these associations was typically higher for medication possession ratio
than for self-reported adherence (Table 5).

Immediate motivational impact
Subjects’ sense of their immediate motivational response to the index session as
measured by their answers to a 7-point Likert-type question was positive and significant
in the Intervention Group but not in the Control Group (p <0.001) (Table 1).
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A response of 4 indicated no change in motivation. The mean response for the question
in the sample as a whole was 5.3 (4.8, 5.8) indicating a moderately positive impact on
motivation from the session. Higher numbered responses were significantly correlated
with shorter history of hypertension and larger improvements in self-reported adherence
at 90 days (Table 5).
Table 1. Index visit and baseline data
Control
Mean
95% CI
Demographics
n
Male
Caucasian
Married
Age in years
Dx in years
Comorbidities
Medications
HTN medications
Blood pressure
n
Systolic
Diastolic
Mean arterial pressure

15
15
11
7
72.5
8.1
10.7
7.7
2.3

(10.8, 11.2)
(6.7, 7.3)
(66.0, 79.1)
(5.8, 10.3)
(7.6, 13.9)
(5.7, 9.6)
(1.7, 2.9)

15
153.3 (145.8, 160.8)
81.5 (75.2, 87.8)
105.4 (100.1, 110.7)

Intervention
Mean
95% CI
15
15
10
7
66.9
8.1
12.0
8.9
3.5

(9.8, 10.2)
(6.7, 7.3)
(60.5, 73.2)
(5.2, 11)
(9.2, 14.8)
(6, 11.7)
(2.2, 4.7)

15
158.1 (150.7, 165.6)
82.4 (73.3, 91.5)
107.6 (100.2, 115.1)

Control
Mean 95% CI

p

1.000
0.703
1.000
0.193
0.968
0.563
0.490
0.135

0.382
0.869
0.636

* X^2, p-value for MMAS 0.602, 0.740; for MPR 1.321, 0.250

Motivation (TSRQ)
n
15
Autonomous
38.2 (36.1, 40.3)
Controlled
15.8 (10.6, 21)
Total
54.0 (47.8, 60.2)
Adherence
Self-report (MMAS)
6.3 (5.4, 7.3)
n (%)
15 (100%)
Low (<6)
4 (27%)
Medium (6 to <8)
6 (40%)
High (8)
5 (33%)
Pharmacy data (MPR)
63.3% (0.47, 0.79)
n (%)
12 (100%)
Nonadherent (<80%)
8 (67%)
Adherent (>=80%)
4 (33%)
Immed. motivation impact
7-point Likert scale
4.3 (3.9, 4.6)

Intervention
Mean
95% CI
15
37.7
14.2
51.9
5.7
15 (100%)
6 (40%)
5 (33%)
4 (27%)
47.4%
14 (100%)
12 (86%)
2 (14%)
6.3

p

(35.1, 40.3)
(8.6, 19.8)
(46.5, 57.2)

0.756
0.684
0.613

(4.5, 6.9)

0.451

(0.31, 0.63)

*
*
*
0.185
*
*

(5.7, 6.8)

0.000
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Changes in blood pressure
Both Groups exhibited decreases in mean SBP and MAP relative to index levels for every
followup period (Table 2). Blood pressure decreases were apparent at 90 days and
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persisted with little additional change through 360-day followup. The mean decline in
SBP was 16.9mmHg (6.3, 27.4) at 90 days and 15.7mmHg (7.2, 24.1) at 360 days.
Significance for 180-day and 270-day data suffered from outsized losses to followup as
discussed below.

In general, the magnitude, duration and statistical significance of the declines in blood
pressure were greater for the Intervention Group, however between Group differences
were not statistically significant. The strength of the relationship of the intervention with
these improvements was low by Pearson correlation, with r = 0.057 between the
intervention binary variable and 90-day change in SBP. At 90-day followup, the
Intervention Group exhibited a mean decline in MAP of 10.3mmHg (p = 0.031) whereas
the Control Group had a mean decline of 7.6mmHg (p = 0.275). Blood pressure changes
persisted through the end of the followup period with mean MAP declines of 12.2mmHg
(p = 0.008) and 6.0mmHg (p = 0.164) for the Intervention and Control Groups
respectively at 360 days.

Higher index MAP was associated with larger declines following the index session. A
1mmHg elevation in baseline MAP was associated with a subsequent decline of
0.862mmHg (0.436, 1.290) at 90-day followup (R2 = 0.485). This effect was consistent
in direction for both Intervention and Control Groups but was greater and more
significant in the Intervention than the Control which underwent percentage declines in
MAP of 8.6% (1.5%, 15.8%) and 5.6% (-7.6%, 18.8%) respectively.
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Table 2. Changes in blood pressure, index visit vs 90-, 180-, 270- and 360-day followup
Mean

Control
95%CI

Mean

Intervention
95%CI

p

! v index

Control
95%CI

p

! v index

Intervention
95%CI

p

SBP
Index
90 days
180 days
270 days
360 days

153.3
139.8
140.4
137.2
141.2

(145.8, 160.8)
(128.1, 151.5)
(128.3, 152.6)
(129.7, 144.6)
(132.1, 150.3)

158.1
139.5
144.5
148.8
141.5

(150.7, 165.6)
(129.8, 149.1)
(128.8, 160.2)
(134.8, 162.7)
(134.4, 148.6)

0.382
0.965
0.691
0.141
0.953

-18.2
-14.3
-16.4
-14.3

(-36.4, 0)
(-28.4, -0.2)
(-24.5, -8.2)
(-29, 0.4)

0.081
0.095
0.003
0.090

-15.6
-11.2
-7.9
-16.9

(-25.9, -5.4)
(-25.4, 3)
(-21.2, 5.5)
(-24.6, -9.2)

0.014
0.184
0.286
0.002

DBP
Index
90 days
180 days
270 days
360 days

81.5
81.1
79.1
80.4
76.1

(75.2, 87.8)
(72.7, 89.5)
(71.2, 87.1)
(74.5, 86.2)
(71.9, 80.3)

82.4
74.0
75.7
78.4
71.5

(73.3, 91.5)
(67.7, 80.3)
(65.2, 86.1)
(71.4, 85.4)
(64.3, 78.6)

0.869
0.195
0.608
0.674
0.296

-2.3
1.1
-3.8
-1.8

(-13.2, 8.6)
(-10, 12.3)
(-10.3, 2.7)
(-8.1, 4.5)

0.687
0.848
0.279
0.588

-7.6
-6.3
-10.5
-9.9

(-17.4, 2.1)
(-14, 1.3)
(-19, -2)
(-17.7, -2.1)

0.155
0.164
0.047
0.032

MAP
Index
90 days
180 days
270 days
360 days

105.4
100.7
99.6
99.3
97.8

(100.1, 110.7)
(92.1, 109.2)
(91.7, 107.4)
(93.7, 104.9)
(93.6, 102)

107.6
95.8
98.6
101.8
94.8

(100.2, 115.1)
(89.3, 102.3)
(88.3, 108.9)
(94.4, 109.2)
(89.4, 100.2)

0.636
0.380
0.884
0.594
0.409

-7.6
-4.0
-8.0
-6.0

(-20.4, 5.2)
(-14.3, 6.3)
(-13.9, -2.1)
(-13.7, 1.8)

0.275
0.476
0.024
0.164

-10.3
-7.9
-9.6
-12.2

(-18.4, -2.3)
(-15.7, -0.2)
(-18.6, -0.6)
(-19.5, -5)

0.031
0.099
0.075
0.008

Changes in motivation
The mean TSRQ response at 90-day followup was suggestive of increased levels of
motivation for both Groups, with a mean response of 55.8 (50.4, 61.1) corresponding to
an increase of 2.7 points (-1.4, 6.8) compared to baseline, however significance of this
relatively small change was limited by sample size (Table 3) and between Group
differences were not statistically significant. Almost all of this effect was due to an
increase of 4.5 points in controlled motivation in the Intervention Group (r = 0.119).
Autonomous motivation was little changed for the sample as a whole with an increase of
0.1 (-2.0, 2.3).

The increase in controlled TSRQ for the Intervention Group was countered by a slight
decline in autonomous motivation. The slight increase in motivation for the Control
Group was evenly distributed between autonomous and controlled motivation.
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Table 3. Changes in motivation as measured by TSRQ, index visit vs 90-day followup
Mean

Control
95%CI

Intervention
Mean
95%CI

p

! v index

Control
95%CI

p

! v index

Intervention
95%CI

p

Autonomous
Index
90 days

38.2
39.0

(36.1, 40.3)
(36.8, 41.2)

37.7
36.5

(35.1, 40.3)
(32.4, 40.6)

0.756
0.293

1.2

(-1, 3.3)

0.311

-1.0

(-4.5, 2.5)

0.590

Controlled
Index
90 days

15.8
16.5

(10.6, 21)
(11.9, 21.1)

14.2
19.5

(8.6, 19.8)
(12.4, 26.6)

0.684
0.493

0.8

(-2, 3.7)

0.569

4.5

(-1.6, 10.6)

0.174

Total TSRQ
Index
90 days

54.0
55.5

(47.8, 60.2)
(49.5, 61.6)

51.9
56.0

(46.5, 57.2)
(47.4, 64.6)

0.613
0.931

2.0

(-2.3, 6.3)

0.318

3.5

(-3.3, 10.3)

0.335

Changes in adherence
Mean adherence improved for the Intervention Group and was close to unchanged for the
Control Group as measured by MMAS and MPR with statistical significance varying by
measure (Table 4). Pearson correlation coefficients between the intervention and
outcome measures were 0.210 and 0.271 for point change in MMAS and percent change
in MPR respectively. Between Group differences were not statistically significant
(MMAS p = 0.349, MPR p = 0.181).

The combined sample underwent almost no change in self-reported adherence at 90 days
with a change of -0.2 (-0.8, 0.4) points on the 8-point MMAS. The Intervention Group
had a mean improvement of 0.5 (-0.5, 1.5) points, however the result was not significant.

The sample as a whole exhibited an increase in mean 360-day medication possession
ratio of 6.3% (0.0%, 14.5%) improving from 54.7% (42.6%, 66.8%) to 60.9% (53.8%,
68.0%) but remaining below the 80% threshold for adequate adherence. The majority of
this change was due to improvement in the Intervention Group where the average MPR
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increased 11.3% (0.0%, 23.3%, p = 0.088) while the Control Group improved by 0.7%
(-8.8%, 9.6%).

Two of the subjects in the Intervention Group had baseline 360-day MPR of zero and
started filling their scripts (with variable consistency) following the index session. This
resulted in a low baseline MPR for the Intervention Group and contributed to its
relatively large increase in mean adherence. Removing these patients from the
calculation results in a mean increase in MPR of 5.0% (p = 0.255) for the Intervention
Group. There were no similar patients in the Control Group.

Improvement in MMAS was positively correlated with index SBP, controlled and
aggregate motivation (TSRQ) at index visit and scores indicating higher immediate
motivational impact from the session. Improvement in MPR was likewise positively
correlated with baseline motivation (controlled and total TSRQ) (Table 5). Lower levels
of improvement and even negative changes in adherence were associated with longer
disease burdens and higher baseline adherence. These relationships were consistent
across both MMAS and MPR. The association between length of diagnosis and
adherence intervention efficacy has been noted in prior studies (22, 66).
Table 4. Changes in adherence as measured by MMAS and MPR, index visit vs 90-day followup
Mean
MMAS
Index
90 days
MPR
Pre-index
Post-index

Control
95%CI

Intervention
Mean
95%CI

p

! v index

Control
95%CI

p

! v index

Intervention
95%CI

p

6.3
6.1

(5.4, 7.3)
(5.4, 6.8)

5.7
6.6

(4.5, 6.9)
(5.9, 7.3)

0.451
0.330

-0.1

(-0.7, 0.5)

0.798

0.5

(-0.5, 1.5)

0.372

63.3%
64.1%

(0.47, 0.79)
(0.55, 0.74)

47.4%
58.7%

(0.31, 0.63)
(0.49, 0.68)

0.185
0.487

0.7%

(-0.1, 0.1)

0.934

11.3%

(0, 0.2)

0.088
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Table 5. Pairwise correlation coefficients
1
2
3
4
1 Age
2 Caucasian
0.33
3 Married
0.13 0.18
4 HTN years
0.26 0.11 0.12
5 Comorbidities
-0.01 -0.25 0.08 0.46
6 Medications
-0.38 -0.21 -0.15 0.27
7 HTN medications
-0.26 -0.20 -0.19 0.42
8 Index SBP
0.08 -0.07 -0.09 -0.04
9 TSRQ Autonomous
-0.23 -0.32 -0.16 0.12
10 TSRQ Controlled
0.08 -0.11 0.19 -0.12
11 TSRQ Total
-0.02 -0.23 0.11 -0.06
12 MMAS
0.25 0.29 0.16 0.37
13 MPR
0.04 0.24 0.30 0.50
14 ! immed. motivation -0.04 0.08 0.01 -0.67
15 90d ! SBP
-0.26 -0.06 -0.07 -0.15
16 90d ! TSRQ Auton.
-0.16 0.02 0.17 -0.18
17 90d ! TSRQ Control. -0.22 -0.20 -0.09 -0.23
18 90d ! TSRQ Total
-0.27 -0.16 0.01 -0.29
19 90d ! MMAS
-0.23 -0.27 0.14 -0.45
20 ! MPR
-0.16 -0.20 -0.27 -0.46
Bolded correlations are significant at the 10% level.

5

6

7

8

9

0.59
0.45
0.08
0.00
-0.32
-0.30
0.02
-0.07
-0.02
0.31
0.02
0.21
0.19
-0.14
0.03

0.62
-0.11
-0.04
-0.36
-0.36
0.10
0.24
0.00
0.34
0.38
0.34
0.48
-0.06
-0.19

0.08
-0.16
-0.24
-0.30
0.10
-0.01
0.12
0.03
0.18
0.19
0.25
-0.19
0.08

0.12
-0.06
-0.01
-0.45
-0.33
0.40
-0.68
-0.17
0.12
0.01
0.57
0.15

-0.45
0.36
0.07
0.44
-0.07
-0.06
-0.33
0.09
-0.10
-0.01
-0.14

10

11

12

13

14

15
16
17
18
19
Index demographics and clinical data

Index motivation metrics
0.91
-0.65
-0.57
0.01
-0.24
0.19
-0.44
-0.27
0.61
0.53

-0.57
-0.42
-0.02
-0.25
0.04
-0.38
-0.30
0.55
0.47

Index adherence metrics
0.65
-0.15 -0.34
Followup data
0.30 0.18 -0.09
-0.01 0.26 -0.01 0.19
0.07 0.11 0.18 0.45 0.02
0.05 0.23 0.14 0.46 0.54 0.85
-0.82 -0.36 0.36 -0.29 0.21 -0.06 0.05
-0.57 -0.82 0.16 -0.07 -0.29 0.00 -0.14 0.28

Pearson correlation coefficients between the intervention Boolean variable and outcome
measures were 0.76, 0.21, 0.27, 0.12 and 0.06 for immediate change in motivation, point
change in MMAS, percent change in MPR, point change in TSRQ and mmHg change in
SBP respectively.
Losses to followup
Losses to followup varied by dataset. Blood pressure followup window periods
sometimes did not coincide with clinic visits and thus no blood pressure data were
available in CPRS for some patients for some periods (Table 6). Losses to followup for
both Control and Intervention Groups for the 90-day and 360-day samples were 33% and
27% respectively. The 180-day and 270-day blood pressure datasets had even larger
losses. Baseline blood pressure characteristics for those lost to followup at 90 days were
asymmetric between Groups. The Control Group lost 5 subjects with average index
blood pressures below the Group’s mean. Conversely, the Intervention Group lost 4
subjects with relatively high index blood pressures.
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Loss to followup for the questionnaire data was of lower magnitude than that for blood
pressure measurements. Subjects were considered lost if the co-investigator was
unsuccessful in contacting them despite three attempts via phone. However, OLS
regression indicates a very weak positive relationship between index TSRQ and change
in TSRQ with a slope not significantly different from zero. Thus, while the Control
Group lost subjects with relatively high index motivation and the Intervention Group lost
relatively low motivation subjects, this asymmetry seems unlikely to have caused
significant bias in their subsequent changes in TSRQ. Both Groups lost patients with
lower index adherence as measured by MMAS.

One subject died of an unrelated illness during the year following the index visit. The
subject had already undergone his followup questionnaires but analysis of his script fill
behavior was limited to 180 days before and following the index visit.
Table 6. Analysis of losses to followup for blood pressure, motivation and self-reported adherence data
Control
Intervention
Control
Intervention
Mean at Loss to
Mean at Loss to
Mean at Loss to
Mean at Loss to
n
index followup
n index followup
n index followup
n index followup

SBP
Index
90 days
180 days
270 days
360 days

15
10
7
11
10

153.3
158.0
154.7
153.5
155.5

0%
33%
53%
27%
33%

15
11
6
8
11

158.1
155.1
155.7
156.6
158.5

0%
27%
60%
47%
27%

TSRQ
Index
90 days
MMAS
Index
90 days

15
13

54.0
53.5

0%
13%

15
12

51.9
52.5

0%
20%

15
13

6.3
5.4

0%
13%

15
12

5.7
4.9

0%
20%

Feasibility
An additional seven subjects were enrolled from June 15 to August 15, 2011 (the year
following the RCT) as part of the feasibility component of this pilot study. These
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subjects were introduced to the intervention by a doctor (n = 4) in the course of a regular
Clinic appointment or a nurse (n = 3) specializing in the instruction of patients in the use
of home blood pressure monitoring systems. An identical script was used for the
intervention but was not required to be read by the clinician. The aim was to assess the
viability of the use of the device and intervention in everyday clinical practice. No data
on these patients were collected beyond demographics and no subjects served as controls.

The physician reported positive reception from his patients and favorable opinion of the
intervention, describing it as “incredibly easy” to use and “a very impressive tool” for
patient education. His assessment of patient experience was that they were typically
“very eager” to participate when asked. Patients were interested in the intervention and
smiled, showing positive body language while using the device. He estimated that a
typical intervention took 5 minutes of which the majority was usually occupied by the
consent process. He believed that the intervention was suitable for most people
regardless of educational level, and that “a large segment of [his] patients” would find the
intervention useful. However, he was unsure whether the intervention would actually
change adherence behavior and noted that “it certainly can’t hurt”. He felt that the
intervention was a novel tool for use in addition to the traditional printed, web-based and
verbal vectors.

The physician believed that he would likely make use of the device and intervention in
clinical practice but that it might be best employed by a healthcare extender such as a
nurse or health technician. He noted that it was sometimes hard to find time to employ

41
the intervention given all that is required of a primary care visit and that use of the device
requires no specialized knowledge or skillset which would preclude use by a nonphysician.

The nurse also reported very positive reception from her patients. It was easy to find
suitable patients and they were generally eager to participate and interested in the device
once it was explained to them. She felt that the device was easy to operate but that the
pressure seemed to leak out over time. She estimated that a typical intervention took 15
minutes including explanation of the balls’ use and the meaning of the pressure
differences. She estimated that only 5 minutes of this time was used for the actual
intervention, the remainder dedicated to the consent process.

She felt that the device could easily be incorporated into her clinical practice and would
“definitely” use the device were it available. She noted that “this intervention may
motivate them and encourage them to be more serious about taking their medication... I
definitely feel that this intervention would help. I always think that visual aids and
hands-on always helps a patient learn... will definitely improve patient adherence
behavior”. She concluded, “this is a fairly simple intervention and would be well suited
for several types of patients. I also do group visits with diabetes and hypertension
[where] I would like to use this intervention, if available, as a teaching tool.”

There was no formal assessment of patient satisfaction or opinion of the intervention.
There were no withdrawals, complaints or adverse events associated with the study.
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Discussion
Poor adherence to prescribed antihypertensive medication has been characterized by the
National Council on Patient Information and Education as “America’s other drug
problem” (114). More than sixty-five million Americans and one billion people
worldwide have blood pressure high enough to warrant treatment. Studies in the United
States consistently report adherence to antihypertensive regimes of 30%-60%, well below
the 80% threshold commonly associated with consistent blood pressure control. The
sequelae of untreated hypertension are serious and their burden to the patient and
economic cost to society are substantial. Prior inquiries have established that patients are
less apt to adhere to prescribed treatments for asymptomatic diseases (14). Thus, it seems
worthwhile to investigate the effect of providing a conscious, subjective awareness (i.e., a
symptom) to the usually asymptomatic pathology of hypertension. The aim of this pilot
randomized controlled study was to determine the utility of a somatosensory educational
intervention to improve adherence to prescribed antihypertensive regimes and the
feasibility of a full-scale trial. The results of the inquiry suggest that the intervention
shows promise in promoting adherent behavior and may encourage clinically useful
improvements in blood pressure. The results of recruitment efforts and the comments
from practitioners suggest that a larger scale study is feasible in the clinical setting. The
intervention presents feedback directly calibrated to the individual patient’s level of
disease in the moment, it is inexpensive, simple, noninvasive, easily understood and
appears feasibly integrated into the rhythm of the typical clinic visit. A larger study is
required to confirm these results and establish their statistical significance.
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Several metrics of adherence were investigated as well as motivation and blood pressure
before and after the intervention in order to gain a preliminary assessment of clinical
utility. Generally speaking, the mean changes in measures of interest were encouraging
for the intervention but significance and generalizability were seriously limited by sample
size and homogeneity. Cohen’s Rule of Thumb classifies the effect size of the
Intervention on immediate motivational impact as “high” with a correlation of 0.76.
Higher levels of immediate motivational impact, in turn, were significantly associated
with greater subsequent improvement in self-reported adherence. Effect sizes on the
outcome measures of point change in MMAS, percent change in MPR, point change in
TSRQ and mmHg change in SBP were classified as “small” (0.10 to 0.25) to “medium”
(0.25 to 0.50) (115). However, modest effect size does not preclude clinical relevance
particularly in the case of low cost, high prevalence interventions (116).

These size effects are consistent with those found by Roter and colleagues whose metaanalysis of efforts to improve antihypertensive adherence noted larger intervention effect
sizes on indirect measures such as MPR and small effects on subjective measures such as
MMAS and health outcomes such as SBP (71). This discrepancy may be explained by a
possible ceiling effect in index visit MMAS reducing room for post-intervention
improvement as compared to changes in MPR and blood pressure which are not limited
by the same ex ante inflation.
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Scientists have identified many factors associated with poor adherence in the treatment of
hypertension. Demographic, economic, disease- and treatment-specific variables all play
a role. The disease is largely insensible and many of the medications are associated with
serious side effects including sexual dysfunction, cough, dizziness, nausea, headache and
other effects of autonomic dysregulation. Furthermore, unlike treatments for other
illnesses, antihypertensives do not generally provide negative reinforcement in the form
of relief from consciously experienced symptoms. For a patient considering taking
his/her antihypertensives, the drawbacks of adherence are quite clear: side effects,
inconvenience and money. The benefits are usually nebulous - “long life”,
“cardiovascular health”, “improved quality of life” - and the risks of nonadherence are
equally abstract, distant and uncertain. The pathology itself is detected by an occult and
unexplained process, measured and discussed using a ratio of two undefined numbers
presented in the unhelpful units of “millimeters of Mercury”. In one survey of 587
patients under treatment for hypertension, fully 80% reported reservations about taking
their antihypertensive medicine and 66% preferred to lower their blood pressure without
medication (117).

There is a substantial body of inquiry seeking to identify successful interventions to
improve antihypertensive adherence and clinical outcomes. Categories of intervention
include education, dose simplification, motivational approaches and combinations of
these efforts. Modalities include lecture, interactive sessions, improved access, selfmonitoring, reminders and rewards among many others. Although not amounting to a
consensus among researchers, several reviews cite advantages to multi-approach, patient-

45
specific interventions (51, 69, 71, 72, 74). Unfortunately, such approaches are typically
complex, expensive and difficult to implement. Thus, there is interest in simple, patientspecific interventions capable of producing clinically relevant improvements with the
possibility of realistic administration during the office visit (45). This individually
tailored intervention addresses the problems of expense and complexity in that it is
unimodal, easily administered by one caretaker, requires no followup reinforcement and
employs a device fabricated from widely available, inexpensive components.

Data on the benefits of educational sessions are mixed at least in part due to widely
varying modalities, venues, frequencies of teaching sessions and outcome measures. In
the largest, best-designed and most often-cited interventions, education-only efforts fare
poorly. Of the six educational RCTs sufficiently rigorous to be included in the latest
Cochrane Review of interventions to improve antihypertensive adherence (51), only one
relatively small trial (n = 110) of group education sessions by Marquez-Contreras et al
demonstrated improved adherence but evinced no effect on clinical outcomes (118).
Pierce and colleagues, in a study of 115 patients, found that a set of four office-based
educational sessions had a larger impact on blood pressure control and adherence by pillcount than daily pressure monitoring (54). In contrast, an earlier landmark study by
Sackett et al found that mastery by 230 steelworkers of facts regarding hypertension and
its sequelae provided and reinforced at work elicited no improvement in adherence (57).
Kirscht et al, in a study of 400 almost entirely Caucasian patients identified no
improvement in adherence from an educational session employing written material as
part of four sequential multi-approach interventions. Similarly, Webb and colleagues
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noted no improvement in either adherence or blood pressure in 123 low-income AfricanAmerican patients who received additional education and psychosocial counseling when
compared to those receiving regular family physician care (55). Finally, Kerr and
colleagues identified significant improvements in pill-count adherence from
combinations of self-monitoring and education, but no such improvements when
education was utilized alone (52). Were the results of the present inquiry supported in a
larger study, this intervention may add a standalone educational initiative capable of
encouraging improvements in medication possession and blood pressure management to
the armamentarium of clinicians and researchers.

Self-reported medical adherence, the primary outcome as measured by mean MMAS,
was improved in the Intervention Group and slightly decreased in the Control. Greater
levels of improvement in MMAS were associated with responses indicating greater
immediate motivational impact from the intervention. Encouragingly, this latter metric
evidenced a “high” size effect from the intervention according to Cohen’s Rule of
Thumb. As with prior studies, self-report in the sample appeared to overstate adherence
levels both at baseline and followup when compared to more objective measures.

Intervention Group MMAS responses demonstrated a mean increase of 0.5 points out of
8 (p = 0.372) moving from a “low” level of adherence (<6 points) to “medium” (6 to <8
points). The study was powered to detect a difference of 1.5 points and thus could not
establish the significance of this result. However, were this difference to persist upon
further investigation, such an improvement would likely accompany clinically relevant
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blood pressure improvements on average. Crossing this threshold has been shown to
have clinical significance. In a study of 1367 patients, Morisky et al found that 67.2% of
“low” adherers by MMAS had uncontrolled hypertension compared to 55.2% of
“medium” adherers (85). Krousel-Wood et al, in a study of 116 patients, found that the
odds-ratio for non-persistence (<80% adherence by MPR) decreased from 8.2 to 2.3 for
the same change in MMAS category (87).

In order to validate and explore the clinical significance of the primary outcome, three
secondary outcomes were examined. The results of these analyses also suggest a positive
impact from the intervention on medication possession ratios, motivation for adherence
and clinically relevant improvements in blood pressure.

Medical adherence as measured by 360-day MPR increased 11.3% (p = 0.088) in the
Intervention Group and 0.7% (p = 0.934) in the Control. However, the study was not
sufficiently powered to detect a between-Group difference. Of all the outcome variables,
the estimate of size effect by Pearson correlation was highest between the intervention
and MPR. Unfortunately, the average post-intervention MPR of 58.7% is still well below
the threshold of 80% commonly used to define adequate adherence for antihypertensives.
This persistence is perhaps unsurprising given that the study sample included only
patients with uncontrolled hypertension despite treatment. This result emphasizes the
multifactorial approach of successful interventions; on average, use of this device alone is
unlikely to transform a nonadherent hypertensive into an adherent one as measured by
MPR.
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Self-Determination Theory proposes that autonomous motivation is an essential
component of durable changes in health behaviors (46). Subjects’ response to the
question of immediate change in motivation substantially and significantly favored the
Intervention (p < 0.001) and more positive responses to this question were significantly
associated with greater improvements in MMAS. This question was intended to gauge
patients’ “gut” response to the intervention outside of any changes that it may or may not
precipitate in their motivation or behavior. It was also conceived as a safeguard against
poor questionnaire followup. Because the question was not vetted for content validity,
predictive validity or reliability, the importance of this result is unclear. Nevertheless,
this result and the clinicians’ feedback are encouraging for a larger study as they suggest
that patients find the intervention interesting and useful as a heuristic device.

Although patients’ endorsement of the immediate impact of the intervention on
motivation was encouraging, the question did not distinguish between forms of
motivation and the followup data are much more ambiguous. None of the changes in
motivation were significant at 90 days and mean changes indicated an increase in the
controlled motivation subcategory. In fact, there is no reason to believe that one session
of the intervention should have a durable impact on feelings of competence or encourage
autonomous forms of motivation. On the contrary, it is possible that the intervention was
viewed by subjects as an attempt to elicit feelings of guilt or shame which are examples
of controlled influences and are usually counterproductive.
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Higher levels of controlled motivation are often (but not always (95)) associated with
poorer adherence and health outcomes. However, SDT also proposes that behavioral
change involves the internalization of initially external influences (47) and that
motivation is a dynamic concept in which a patient experiencing a controlled motivation
type can eventually internalize this influence (46). It is plausible that an initially
controlled influence from the intervention could ultimately become integrated into more
self-derived sources of motivation and enhance the patient’s sense of self-efficacy in the
longer run.

Both the Control and Intervention Groups appeared to experience durable, clinically
useful, statistically significant mean improvements in SBP and MAP. Mean
improvements were greater in magnitude, duration and statistical significance in the
Intervention Group. In a landmark recommendation, The National High Blood Pressure
Education Program emphasized that a sustained reduction of even 5mmHg in SBP was
shown to reduce mortality from cardiovascular disease by 7% per year (119). Thus, were
a larger study to affirm these reductions in blood pressure, such changes would have
clinical relevance.

Any effect from the session on blood pressure was heavily confounded by index visit
changes in number of antihypertensives. The average subject increased their number of
antihypertensive scripts by 0.6 (p = 0.025) during the index visit. This change was seen
equally in both Groups. New antihypertensives given at index visit would provide
explanation for the symmetry of blood pressure improvements between Groups and the
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poor estimate of the intervention effect size on change in 90-day SBP despite a
significant improvement in MPR. Interestingly, regression of blood pressure changes on
number of new scripts did not result in significant slope coefficients or measures of
association. In addition, new medications were evenly distributed between Groups and
so would not explain the greater apparent durability of improvements in the Intervention
Group.

A number of different behaviors are prescribed and proscribed with the ultimate goal of
blood pressure control. Thus, it is possible that the index visit (both Control and
Intervention sessions) encouraged pressure reductions through behavioral changes not
captured by the adherence and motivation outcome measures utilized for this study.
Indeed, several trials of educational interventions have noted similar reductions in blood
pressure in control Groups exposed to regular care, particularly for studies which focus
on patients with poor medical adherence (49, 59). Studies of biases have found that rates
of adherence in clinical trials are typically high due to attention effect (120). However,
while both Groups received the informational talk on the benefits of antihypertensive
adherence, it seems unlikely and is inconsistent with prior studies (14) to believe that
such a brief and unexceptional lecture precipitated the improvements noted in the present
study. It may be more plausible to assert that hypertensive patients under care of primary
care physicians will, on average, achieve a fall in their blood pressure through various
avenues including addition of new drugs - an effect which the intervention may have
augmented.
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Baseline blood pressure characteristics for those lost to followup at 90 days were
asymmetric between Groups. The Control Group lost 5 subjects with average index
blood pressures below the Group’s mean. Conversely, the Intervention Group lost 4
subjects with relatively high index blood pressures. As discussed above, 90-day change
in blood pressure was inversely and significantly related to index SBP with a slope of
roughly -1. Thus, the magnitude of the Control Group’s reduction in BP at 90 days may
have been biased upwards (by roughly 5mmHg) and that of the Intervention Group may
have been biased downwards (by roughly 3mmHg). The combination of these influences
could have led to a low estimate for impact on blood pressure from the intervention.

Correlations between demographic data, baseline adherence and changes in adherence
metrics were largely in line with prior inquiries and common sense. Baseline blood
pressures were negatively and significantly correlated with better adherence as measured
by both self-report and prescription data. Index motivation was negatively correlated
with duration of disease, number of comorbidities and number of medications. The two
metrics for index medical adherence (MMAS and MPR) were positively correlated. In
addition to lower index blood pressure, higher baseline values for both adherence metrics
were associated with lower scores for controlled motivation, higher scores for
autonomous motivation, longer length of diagnosis and Caucasian race.

Improvement in MMAS was positively correlated with index SBP, controlled and
aggregate motivation (TSRQ) at index visit and a higher immediate motivational impact
from the session. Improvement in MPR was likewise positively correlated with baseline
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motivation (controlled and total TSRQ). Longer disease burdens were associated with
higher baseline adherence, reduced immediate motivational impact as well as lower
levels of improvement and even negative changes in adherence by MMAS and MPR.

Feasibility of a larger study
The feasibility of a larger study was evaluated through implementation of a small number
of interventions on a randomized convenience sample of patients at a busy primary care
clinic, followed by structured interviews with clinicians who instituted the intervention in
their everyday practice. These results suggest that a larger scale study wherein the
intervention is administered by working care extenders such as RNs, PAs and/or research
assistants in the primary care setting is feasible and would not be unacceptably disruptive
to the everyday flow of clinical practice.

Patients typically expressed curiosity regarding the device and appeared pleasantly
surprised at the novelty of the concept. There were no complaints or withdrawals from
the study and patients typically responded with interest and curiosity when the
intervention was described and during the demonstration. The physician who employed
the intervention in his practice felt that it was simple, fast, useful and very well-received
by his patients. However, as time is extremely limited in the primary care visit, he
recommended involvement of care-extenders to facilitate enrollment. The nurse reported
very positive reception from her patients and she felt that the device was easy to operate
and useful as a motivational tool. She felt that the intervention could easily be
incorporated into her clinical practice and would “definitely” use the device for her
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individual patient visits as well as group education sessions, were it commercially
available.

The consent and questionnaire processes represent at least half of the 10-15 minutes
required for the intervention. The physician reported that these steps made it difficult to
incorporate the study into his clinical schedule. Thus, while the device may represent a
useful and viable intervention by itself, it does not appear feasible to ask busy primary
care doctors to bear the burden of the paperwork associated with a larger study.
Administration of the intervention by care-extenders may provide benefits outside of any
derived from the heuristic itself; one study of 457 participants found that patients who
received supplementary care from specially trained nurses had better blood pressure
control and medical adherence behavior when compared to those who received standard
primary care (56).

Mechanistically, implementation of a larger study appears feasible. In 2009, the VACT
Primary Care Clinic treated 47,044 patients of which 25,474 (70 people per workday)
were hypertensive by ICD-9 code. An estimated 50 to 70% of such patients could be
expected to have SBP greater than 140mmHg despite treatment (11, 56). One person
working for one month was able to enroll 30 subjects. This suggests that the target of
120 patients could be reached in a reasonable amount of time with one or two additional
personnel trained to perform the intervention and associated informed consent. Beyond
simply increasing the number of people enrolling subjects in the same manner as in the
pilot study, a number of additional points of contact may be explored.
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Administration of the intervention in additional venues may allow for increased
enrollment and could validate the use of the intervention by a wider group of
professionals. Triage or check-in areas, counseling, group sessions (for diabetics,
hypertensives and other patients with chronic diseases), and blood drives all present such
opportunities and typically are less time-restricted than the primary care office visit. The
pharmacy is another point of contact in which the patient is thinking about his/her health
and may be amenable to participation. Pharmacies offer the added advantages of
trainable health professionals, less rigid scheduling than the clinic and, oftentimes,
automated blood pressure machines for customer use.

Prior inquiries conclude that multiple points of contact increase the likelihood of success
for a given adherence intervention (14, 34). A future study might examine whether serial
applications of this intervention for an adherent patient provides a tangible sense of their
progress in reaching their blood pressure goal. Deci et al, in their elucidation of the
principles of SDT, note that positive feedback is associated with internalization of
external motivations (46). There is evidence that repeated interventions and positive
feedback encourage the process of motivational internalization and medical adherence
(50). Johnson and colleagues evaluated different forms of feedback on antihypertensive
adherence, finding that regular blood pressure monitoring had the single most significant
influence, above that of information from the physician, family or the media (23). Such
reinforcement may be associated with increased sense of accomplishment, competence
and autonomous motivation. The present intervention may serve as a possible corollary
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to routine blood pressure measurement, intended to give the patient a conscious, tangible
manifestation of the numbers recorded in his/her chart and the progress that they
represent.

One strength of this intervention is that the degree of feedback increases with the severity
of disease. In informal testing, it takes several squeezes to notice a difference of 1020mmHg but higher differences than this are quite easily detected. The higher a person’s
SBP, the greater the difference in pressure that they feel upon squeezing the two bladders
and the faster their “hypertensive” arm gets tired. Presumably, the emotional weight and
educational value of the intervention increases in proportion to the magnitude of the
pressure difference experienced and thus with the severity of disease. It seems logical to
believe that the psychological impact, motivational utility and degree of improvement in
outcome variables would be more pronounced for higher pressures. The present study
was insufficiently powered to explore this question and may provide an interesting
avenue of exploration for a larger inquiry. Further investigations may benefit from a
higher blood pressure cutoff value for screening purposes as well as targeting patients
early in the course of their disease in hopes of maximizing changes in adherence.

Limitations
All subjects were male veterans which seriously limits the generalizability of the results
of this pilot study. In addition, the sample size was often insufficient to establish
statistical significance of the intra-Group outcomes and in cases where significant
improvements in the Intervention Group were identified, significant inter-Group
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differences with the Control were not always established. In order for the Intervention
Group’s mean outperformance in MMAS (the primary outcome) of 0.6 to have been
significant the required sample size would have been 329 subjects after losses to
followup, assuming the realized standard deviation of 1.8, power = 0.80 and p = 0.05.
The modesty of this inquiry was necessitated by limited resources and the desire to
minimize the disruption to the activities of the Clinic. The exclusion of subjects with
history of advanced vascular compromise or atherosclerosis was intended to reduce the
chance of adverse events associated with participation in the intervention. However, it is
possible that this group of patients would benefit substantially from improved adherence
to antihypertensive prescriptions and their exclusion from the study limits its relevance to
clinical practice. As physical effort involved in participation is quite minimal, the risk to
these patients is likely small and a larger study should consider their inclusion.

The study’s design limited its utility as a pilot. More data on recruitment, uptake of
intervention, patient satisfaction and acceptability should have been sought. Because a
convenience sample was employed, very few people decided not to participate, however
a larger study may approach sequential patients, likely resulting in higher rates of refusal.
Physicians recommending their patients for the study may have selected for more
agreeable personalities which could have introduced additional confounding to the
adherence metrics. Nevertheless, the results of the immediate motivational impact
question and clinician interviews suggest that patients were amenable and generally
enthusiastic about participation, or at least did not find the intervention counterproductive
or unpleasant.
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For practical reasons, the process of randomization and Group allocation was known to
the enrolling co-investigator. Due to their necessary participation in the intervention,
subjects were also aware of their status in the study. The effect of the former may have
led to selection or measurement biases while the latter may have encouraged attention
bias.

The question gauging the immediate motivational impact of the session was developed by
the investigators and had no external or predictive validation outside this study. The
question used the term “motivation” but it did not define this word and it did not attempt
to parse out autonomous and controlled components. As a result, comparability with 90day TSRQ responses is limited.

As discussed above, index levels for self-reported adherence and medication possession
were significantly correlated. However, changes in these metrics were positively but not
significantly related. Any relationship between the two was likely weakened by the
difference in timing between the administration of the MMAS at 90 days and the yearlong scope of the MPR. It also appears that MMAS responses were subject to ceiling
effect with significant overestimation of index adherence by self-report allowing little
space for improvement ex post.

The measurement of medication possession ratio presented several challenges. The
model was highly detailed and required manual input of several thousand datapoints.
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Changes in medication classes or brands during the study period were not examined. It is
possible that such a change may produce an impact on adherence that would be
erroneously attributed to the session. While the model does include drug names, it does
not consider whether medication adherence rates varied with drug class. A prior study
found that averaging MPR data across antihypertensive classes did not mask any classspecific differences in adherence (87). Data regarding non-VA medications were
inconsistent. In one Intervention and two Control subjects, such data was missing and
these patients were not included in MPR calculations. It is plausible that patients who fill
their meds outside the VA are wealthier or have better access to the healthcare system,
both variables found to be associated with higher adherence. Finally, the VA pharmacy
presents a semi-closed system in which data for most patients are readily available. A
larger study outside the VA system would have the added challenge of gathering MPR
data from a variety of sources.

Review of prescription records provides data on gross consumption patterns but not on
more granular adherence phenomena: for example, if the subject is consistently missing
his weekend doses, nighttime doses or if he misses doses sporadically. These questions
could have been addressed by MEMS and allowed for a richer analysis of changes in
adherence. Each visit is an opportunity for changes to medical plan of treatment and
some patients have their medications changed or supplemented with new medications.
As the index session occurred immediately following a routine primary care visit, new
medications or new dosages were often introduced on the same day as the session. If the
intervention had any effect, it seems plausible that this effect would be greatest at the
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time of the session which, in this case, coincides with new scripts being written. This
“white-coat adherence” would have the effect of augmenting any MPR changes than had
the intervention occurred between medical visits (121) along with the confounding
effects of new antihypertensives introduced at the time of the intervention.

Similarly, it is often difficult to distinguish between different types of nonadherent
behavior. For example, two separate analyses may report 50% adherence but this can
indicate that either 100% of patients stopped therapy halfway through the period or that
100% of patients took half their medicine for the entire period. A rough analysis of the
pharmacy data indicate that the change in the number of days with no pills taken was
inversely proportional to the change in MPR. This suggests that changes in adherence
were more likely to include all hypertension scripts rather than piecemeal decisions by
the patient to improve adherence to just one or two drugs. Furthermore, pairwise
correlation and OLS regression analyses were limited to those subjects for whom
complete MMAS followup was possible.

There were substantial losses to followup in the blood pressure data as those without
appointments within 15 days of followup dates were excluded from these calculations
which reduced sample size most substantially for the 180- and 270-day comparisons.
This problem could have been ameliorated by taking averages of blood pressure data over
wider windows rather than discrete, periodic readings. Lost subjects may have been
more prone to poor adherence and their loss may have resulted in overestimation of postintervention adherence in both Groups.

60

Conclusions
The results of this inquiry suggest that a brief educational intervention designed to
provide a somatosensory manifestation of the patient’s disease process shows promise in
promoting adherent behavior and clinically useful reductions in blood pressure in poorly
controlled hypertensives. A larger study appears feasible and is required to confirm and
investigate the statistical significance of these results.

Should further studies prove encouraging, there may be potential use for this device in
several healthcare-associated venues. It is simple, inexpensive, fast and noninvasive and
thus potentially useful for primary care physicians, nurses, PAs, or pharmacists,
particularly those working with high-prevalence populations.
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